Published in Circulation on October 01, 1993
Diagnosis Exclusion of Recurrent Deep Vein Thrombosis of the Lower Limbs (ULTREC) | NCT03868956
Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 2.50
Diagnosis of pulmonary embolism. CMAJ (2003) 1.31
Recurrent venous thromboembolism: what is the risk and how to prevent it. Scientifica (Cairo) (2012) 0.82
Negative D-dimer result to exclude recurrent deep venous thrombosis: a management trial. Ann Intern Med (2004) 0.80
One versus two years of elastic compression stockings for prevention of post-thrombotic syndrome (OCTAVIA study): randomised controlled trial. BMJ (2016) 0.75
Acute on chronic venous thromboembolism on therapeutic anticoagulation. Case Rep Emerg Med (2013) 0.75
Diagnosis and Treatment of Lower Extremity Deep Vein Thrombosis: Korean Practice Guidelines. Vasc Specialist Int (2016) 0.75
Analysis of the accuracy of the Wells scale in assessing the probability of lower limb deep vein thrombosis in primary care patients practice. Thromb J (2015) 0.75
Medical management of venous thromboembolic disease. Ochsner J (2000) 0.75
The long-term clinical course of acute deep venous thrombosis. Ann Intern Med (1996) 6.87
Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. BMJ (1998) 6.07
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology (1997) 5.53
Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med (1992) 5.48
Accuracy of clinical assessment of deep-vein thrombosis. Lancet (1995) 3.45
Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med (1996) 3.42
Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med (1997) 3.35
Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet (1992) 2.44
Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology (2000) 2.44
Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost (2004) 2.28
A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost (2010) 2.08
Severe arterial cerebral thrombosis in a patient with protein S deficiency (moderately reduced total and markedly reduced free protein S): a family study. Thromb Haemost (1989) 2.04
Psychological aspects and coping in haemophilic patients: a case-control study. Haemophilia (2003) 1.98
Detection of human herpesvirus 6 in plasma of children with primary infection and immunosuppressed patients by polymerase chain reaction. J Infect Dis (1995) 1.94
High dose frusemide in established acute renal failure. Br Med J (1973) 1.91
Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med (1999) 1.81
Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer (1994) 1.81
Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period. J Hepatol (1998) 1.79
A simple clinical model for the diagnosis of deep-vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnostic process. J Intern Med (1998) 1.76
Natural history and prognostic factors for chronic hepatitis type B. Gut (1991) 1.75
The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med (1997) 1.75
Megakaryocytes endocytose and subsequently modify human factor V in vivo to form the entire pool of a unique platelet-derived cofactor. J Thromb Haemost (2005) 1.73
Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet (1992) 1.73
Features of essential thrombocythaemia in childhood: a study of five children. Br J Haematol (2000) 1.67
Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med (1997) 1.57
Thromboelastometry for guiding bleeding management of the critically ill patient: a systematic review of the literature. Minerva Anestesiol (2014) 1.57
Nomograms for the administration of unfractionated heparin in the initial treatment of acute thromboembolism--an overview. Thromb Haemost (2000) 1.51
A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol (2009) 1.47
Interaction of asialo von Willebrand factor with glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and mediates platelet aggregation. J Clin Invest (1985) 1.44
Mild bleeding diathesis in a boy with combined severe haemophilia B (C(10400)-->T) and heterozygous factor V Leiden. Haemophilia (2001) 1.43
Antiphospholipid antibodies, recurrent thromboembolism, and intensity of warfarin anticoagulation. Thromb Haemost (1996) 1.42
Some structural properties of the cholinergic receptor protein in its membrane environmental relevant to its function as a pharmacological receptor. Cold Spring Harb Symp Quant Biol (1976) 1.42
Use of an algorithm for administering subcutaneous heparin in the treatment of deep venous thrombosis. Ann Intern Med (1998) 1.41
Factor VIII/von Willebrand factor abnormalities during L-asparaginase treatment in patients with acute lymphoblastic leukemia. Acta Haematol (1988) 1.40
Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol (1994) 1.40
Indirect study of thrombopoiesis (TPO, reticulated platelets, glycocalicin) in patients with hereditary macrothrombocytopenia. Eur J Haematol (2000) 1.40
Cooperative signaling between alpha(6)beta(4) integrin and ErbB-2 receptor is required to promote phosphatidylinositol 3-kinase-dependent invasion. J Biol Chem (2000) 1.40
The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica (1997) 1.39
Duration of anticoagulation and risk of recurrent thromboembolism in carriers of factor V Leiden or prothrombin mutation. J Thromb Haemost (2008) 1.39
Asymptomatic homozygous nt 20210 G to A prothrombin polymorphism in two blood donors belonging to two different kindreds. Clin Appl Thromb Hemost (1999) 1.39
Clinical and laboratory expression of associated thrombophilic conditions (homozygous/heterozygous factor V Leiden mutation and heterozygous prothrombin variant 20210A) in an Italian family. Blood Coagul Fibrinolysis (2000) 1.38
Prothrombin time using thromboplastins of different origin in hemophilia BM patients. Am J Hematol (1994) 1.38
Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology (1986) 1.38
Failure of computerized impedance plethysmography in the diagnostic management of patients with clinically suspected deep-vein thrombosis. Thromb Haemost (1991) 1.32
The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood (1996) 1.29
von Willebrand factor interaction with the glycoprotein IIb/IIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia. J Clin Invest (1986) 1.28
Fibrosis progression in initially mild chronic hepatitis C. J Viral Hepat (2006) 1.26
Novel SACS mutations in autosomal recessive spastic ataxia of Charlevoix-Saguenay type. Neurology (2004) 1.26
Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology (1997) 1.24
Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. J Infect Dis (1987) 1.23
Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost (1999) 1.23
Interaction of purified type IIB von Willebrand factor with the platelet membrane glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and initiates aggregation. Proc Natl Acad Sci U S A (1985) 1.23
Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology (1990) 1.23
Upper extremity deep vein thrombosis. Curr Opin Pulm Med (1999) 1.19
Autoimmune thrombocytopenia (AITP) and thyroid autoimmune disease (TAD): overlapping syndromes? Clin Exp Immunol (1998) 1.18
Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. Arch Intern Med (1994) 1.17
A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation. Blood (1997) 1.16
An in vitro analysis of the combination of hemophilia A and factor V(LEIDEN). Blood (1997) 1.14
Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices. Gastroenterology (1992) 1.10
Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer (1998) 1.10
Acute coronary disease in essential thrombocythemia and polycythemia vera. J Intern Med (1998) 1.10
Cellular immunity to the hepatitis B virion in acute hepatitis type B. Clin Exp Immunol (1983) 1.08
It is not sure yet whether the nt 20210 G to A prothrombin polymorphism represents a cause of familial venous thrombophilia. Blood Coagul Fibrinolysis (1999) 1.08
"Hypocoagulable" thromboelastography profiles in patients with cyanotic congenital heart disease: facts or technical artifacts? Int J Cardiol (2013) 1.07
Prothrombotic activity of oral contraceptives in patients with congenital thrombophilia varies with the defect. Clin Appl Thromb Hemost (2001) 1.07
Two PKR inhibitor HCV proteins correlate with early but not sustained response to interferon. Gastroenterology (2000) 1.05
Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group. Hepatology (1995) 1.05
Effects of early maternal separation of lambs and rearing with minimal and maximal human contact on meat quality. Meat Sci (2005) 1.04
Ischemic stroke in young patients with activated protein C resistance. A report of three cases belonging to three different kindreds. Stroke (1995) 1.04
Thrombosis and hemorrhage in thrombocytosis: evaluation of a large cohort of patients (357 cases). J Med (1991) 1.02
Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study. Thromb Haemost (2001) 1.02
Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood (2000) 1.02
Type IIB von Willebrand factor with normal sialic acid content induces platelet aggregation in the absence of ristocetin. Role of platelet activation, fibrinogen, and two distinct membrane receptors. J Clin Invest (1987) 1.01
Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. Gut (2001) 1.01
Immunosuppressive therapy prevents recurrent pericarditis. J Am Coll Cardiol (1995) 1.01
The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost (1996) 1.01